Results 61 to 70 of about 387,314 (311)

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

THE ROLE OF REPRESENTATIVES IN OPHTHALMIC PATHOLOGY HERPESVIRUS [PDF]

open access: yesAnnals of Mechnikov's Institute, 2012
The goal was to establish a place of herpesviruses (HSV1, HSV2, HHV6, SMV, VZV, EBV) in the etiological structure of the eye’s diseases. The study involved 35 patients diagnosed with recurrent keratitis (15 patients) and viral uveitis (n = 20).
Kashpur NV,   +6 more
doaj  

The enzymes LSD1 and Set1A cooperate with the viral protein HBx to establish an active hepatitis B viral chromatin state [PDF]

open access: yes, 2016
Indexación: Web of ScienceWith about 350 million people chronically infected around the world hepatitis B is a major health problem. Template for progeny HBV synthesis is the viral genome, organized as a minichromosome (cccDNA) inside the hepatocyte ...
Alarcon, V   +9 more
core   +2 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Recognition of viral glycoproteins by influenza A-specific cross- reactive cytolytic T lymphocytes [PDF]

open access: yes, 1980
Two populations of cytolytic T lymphocytes (CTL) generated after influenza A virus infection can be distinguished into one with specificity for the sensitizing hemagglutinin type and a second with cross-reactivity for antigens induced by other type-A ...
Allen, H.   +4 more
core   +2 more sources

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

open access: yesMolecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto   +13 more
wiley   +1 more source

Experience of application of IgY-technology for laboratory diagnostics of viral infections

open access: yesВопросы вирусологии, 2020
Introduction. The well-known advantages of class Y antibodies (IgY) from egg yolks of immunized hens in comparison with class G antibodies (IgG) of laboratory animals traditionally used in laboratory diagnosis of infectious diseases determine the stable ...
A. P. Ivanov   +2 more
doaj   +1 more source

Development of recombinant antigen array for simultaneous detection of viral antibodies. [PDF]

open access: yesPLoS ONE, 2013
Protein microarrays have been developed to study antibody reactivity against a large number of antigens, demonstrating extensive perspective for clinical application.
Yi Liu   +3 more
doaj   +1 more source

Concentration of Complement Fixing Viral Antigens.

open access: yesExperimental Biology and Medicine, 1966
SummaryComplement fixing antigens produced in cell culture by a variety of viruses were concentrated by slow speed sedimentation of undisrupted virus infected cells and removal of the supernatant medium. In most cases, concentration of virus infectivity was demonstrated as well.
K, Schell, R J, Huebner, H C, Turner
openaire   +2 more sources

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Home - About - Disclaimer - Privacy